Biochemical and haematological changes in HIV subjects receiving winniecure antiretroviral drug in Nigeria

Background: hematological and biochemical abnormalities are among the most common clinicopathological manifestations of hiv patients on art. consequently,the development and assessment of indigenous antiretroviral drugs with minimal abnormalities becomes a necessity. the objective of this investigation was to assess potential haematological and biochemical abnormalities that may be associated with the administration of winniecure art in hiv patients undergoing treatment in nigeria. fifty (50) confirmed hiv positive art naïve patients aged 36 ± 10 were observed for haematological and biochemical responses for 12 weeks. haematological responses were assessed thrice at 6 weeks interval using coulter ac-t differential analyser and biochemical indicators (bilirubin,creatine,urea,amylase,alt,alp,ast,albumin) assayed spectrophotometrically. results: the biochemical parameters alp (p < 0.05),alt (p < 0.0001),ast (p < 0.001) and amylase (p < 0.05) slightly increased at the 12§ssup§th§esup§ week,no significant change was observed in plasma creatinine and urea concentrations while albumin levels decreased non-significantly (p > 0.002). haematological results showed consistent reduction of esr,eosinophil,absolute and differential lymphocytes,granulocytes and total wbc in the test subjects throughout the assessment period. conversely,haemoglobin,platelet and pcv increased significantly (p < 0.05). at the 12§ssup§th§esup§ week thrombocytopenia (10.30%) and anaemia (76%) were reduced to 2% and 31% respectively while neutropenia (4.2 to 8%),leucopenia (26.8 to 30%) and lymphopenia (1 to 10%) increased. no cases of neutrophilia,lymphocytosis,eosinophilia and leukocytosis was observed. conclusion: the drug has a reduced haematological abnormalities and normal kidney function was unaffected though there were signs of possible abnormal levels of hepatic enzymes beyond 12 weeks of treatment. © 2013 ibeh et al.; licensee biomed central ltd.